id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-D-0413-0015,FDA,FDA-2008-D-0413,Guidance for Industry on Residual Solvents in Drug Products Marketed in the United States; Availability,Notice,Notice of Availability,2009-11-25T05:00:00Z,2009,11,2009-11-25T05:00:00Z,,2020-05-11T22:59:33Z,E9-28247,0,0,0900006480a5e954
FDA-2008-D-0413-0016,FDA,FDA-2008-D-0413,Guidance for Industry; Residual Solvents in Drug Products Marketed in the United States,Other,Guidance,2009-11-24T05:00:00Z,2009,11,2009-11-24T05:00:00Z,,2024-11-07T22:13:10Z,,1,0,0900006480a5ea63
FDA-2008-D-0413-0002,FDA,FDA-2008-D-0413,Draft Guidance for Industry on Residual Solvents in Drug Products Marketed in the United States; Draft Guidance Document,Other,GDL-Guidance (Supporting and Related Materials),2008-08-07T04:00:00Z,2008,8,2008-08-08T03:23:29Z,,2024-11-12T04:18:23Z,,1,0,09000064806b4622
FDA-2008-D-0413-0001,FDA,FDA-2008-D-0413,Draft Guidance for Industry on Residual Solvents in Drug Products Marketed in the United States; Availability,Notice,NAD-Notice of Availability of Data,2008-08-07T04:00:00Z,2008,8,2008-10-06T13:27:55Z,,2024-11-12T04:18:40Z,E8-18127,1,0,09000064806b410b